Key Points
- CFO Adam Laponis sold 4,000 shares on April 17 at $60 each for a total of $240,000 under a pre‑arranged Rule 10b5‑1 plan, leaving him with 118,694 shares (a 3.26% reduction).
- The April 17 sale is part of recent insider selling that also included 3,000 shares on April 14 (at $55), 2,597 shares on April 9 (at $49.89) and 7,000 shares on February 12 (at $50), indicating notable insider disposition in recent months.
- TWST trades around $62.61 with 50‑day/200‑day SMAs of $49.22/$39.66, has positive revenue growth (+16.9% YoY) but negative EPS and margins, and carries a consensus analyst rating of "Moderate Buy" with an average price target of $47.13.
Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CFO Adam Laponis sold 4,000 shares of the company's stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $60.00, for a total transaction of $240,000.00. Following the completion of the transaction, the chief financial officer owned 118,694 shares of the company's stock, valued at $7,121,640. This trade represents a 3.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Adam Laponis also recently made the following trade(s):
- On Tuesday, April 14th, Adam Laponis sold 3,000 shares of Twist Bioscience stock. The shares were sold at an average price of $55.00, for a total transaction of $165,000.00.
- On Thursday, April 9th, Adam Laponis sold 2,597 shares of Twist Bioscience stock. The shares were sold at an average price of $49.89, for a total transaction of $129,564.33.
- On Thursday, February 12th, Adam Laponis sold 7,000 shares of Twist Bioscience stock. The shares were sold at an average price of $50.00, for a total transaction of $350,000.00.
Twist Bioscience Stock Performance
Shares of TWST stock opened at $62.61 on Wednesday. The company's fifty day simple moving average is $49.22 and its 200-day simple moving average is $39.66. The company has a quick ratio of 3.37, a current ratio of 3.78 and a debt-to-equity ratio of 0.03. The firm has a market cap of $3.84 billion, a PE ratio of -48.91 and a beta of 2.20. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $65.10.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.02). The business had revenue of $103.70 million during the quarter, compared to the consensus estimate of $100.32 million. Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.Twist Bioscience's revenue was up 16.9% compared to the same quarter last year. Equities research analysts expect that Twist Bioscience Corporation will post -1.85 EPS for the current fiscal year.
Institutional Trading of Twist Bioscience
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. MRWM Advisors LLC bought a new stake in Twist Bioscience during the first quarter worth $206,000. Rockefeller Capital Management L.P. raised its position in Twist Bioscience by 28.9% during the fourth quarter. Rockefeller Capital Management L.P. now owns 14,970 shares of the company's stock worth $475,000 after acquiring an additional 3,359 shares in the last quarter. Axxcess Wealth Management LLC bought a new stake in Twist Bioscience during the fourth quarter worth $201,000. Mercer Global Advisors Inc. ADV bought a new stake in Twist Bioscience during the fourth quarter worth $242,000. Finally, Empowered Funds LLC bought a new stake in Twist Bioscience during the fourth quarter worth $58,000.
Analyst Ratings Changes
A number of analysts have recently commented on TWST shares. Barclays boosted their price objective on shares of Twist Bioscience from $50.00 to $55.00 and gave the stock an "overweight" rating in a research report on Tuesday, April 14th. Robert W. Baird set a $50.00 price objective on shares of Twist Bioscience in a research report on Tuesday, February 3rd. TD Cowen reissued a "buy" rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Evercore boosted their price objective on shares of Twist Bioscience from $42.00 to $52.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 3rd. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Twist Bioscience in a research report on Friday, March 27th. Seven analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $47.13.
Read Our Latest Report on Twist Bioscience
About Twist Bioscience
(
Get Free Report)
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
